Abstract
Hepatocellular carcinoma is the second cause of cancer related-death worldwide with few therapeutic options. In this field, the rate of bench-to-bed translation of drugs is very modest, with 70% of drug attrition suggesting that preclinical evaluation should be urgently improved. Besides, recently immunotherapy showed very promising results and constitutes a real breakthrough in the area of HCC treatment. As these treatments aim to restore anti-tumor immunity, animal models including a functioning immune system are essential to allow a relevant preclinical validation. Macek Jilkova et al. describe, in a clear and forceful review which animal models can optimize this research and what are the pros and cons of each of them.
Keywords
Hepatocellular carcinoma, Liver immunology, Animal models, Preclinical drug study